InsiderClue
← All stocks

Definium Therapeutics, Inc.

DFTX Scheduled selling only
CIK 0001813814 #1221 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$721.73K
$721.73K on a plan · $0.00 straight out of an exercise
Sold at will
$0.00
0 of 1 sales
Net
−$721.73K
$0.00 against sales at will

By person

12 insiders · 1 transaction
130×

Robert Barrow holds 130 times base salary in stock. $85.16M of shares against $655.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Robert Barrow last reported holding, valued at $37.94, the price Common Shares was last bought or sold at on the open market here, on 3 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
Barrow Robert
Chief Executive Officer
—
$721.73K (1) scheduled
−$721.73K
2,244,640
1.67%
$85.16M
+814.4%
Karlin Daniel
Chief Medical Officer
—
—
—
803,699
0.5981%
$30.49M
+305.4%
Sullivan Mark
Chief Legal Officer
—
—
—
508,279
0.3783%
$19.28M
+798.7%
Roberts Brandi
Chief Financial Officer
—
—
—
397,905
0.2961%
$15.10M
+43,245%
Wiley Matthew T.
Chief Commercial Officer
—
—
—
362,133
0.2695%
$13.74M
—
Liao Carrie
Chief Accounting Officer
—
—
—
144,923
0.1079%
$5.50M
+42.2%
CRYSTAL ROGER
Director
—
—
—
24,289
0.0181%
$921.52K
+23.8%
Bruhn Suzanne Louise
Director
—
—
—
24,289
0.0181%
$921.52K
+23.8%
Vallone Carol A
Director
—
—
—
21,210
0.0158%
$804.71K
+28.2%
GRYSKA DAVID W
Director
—
—
—
19,900
0.0148%
$755.01K
+56.3%
Krebs Andreas
Director
—
—
—
19,773
0.0147%
$750.19K
+30.9%
Adsett Roger
Director
—
—
—
3,555
0.0026%
$134.88K
—

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 6
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 1
Sales straight out of an exercise 0
Sales at will 0
Transactions with no price 0
Shares from compensation/vesting 1,365,000
History held since 19 Jan 2022